



KIDNEY CANCER RESEARCH PROGRAM (KCRP)

ADVANCING INNOVATIVE RESEARCH TO ELIMINATE KIDNEY CANCER

**FY22
Appropriation
\$50M**

MISSION: To promote rigorous, innovative, high-impact research in kidney cancer for the benefit of Service Members, Veterans, and the American public



Concept Award (CA)
\$100K



Postdoctoral and Clinical Fellowship Award (PCFA)
\$195K

CA AND PCFA DEADLINES

June 23, 2022	July 14, 2022	September 2022	November 2022
Letter of Intent	Full Applications Due	Peer Review	Programmatic Review

ESTABLISHED INVESTIGATORS OPTION

EARLY CAREER INVESTIGATORS OPTION



Idea Development Award (IDA)
\$675K

Early Detection Studies Option	\$700K
Population Science and Prevention Studies Option	\$2M



Translational Research Partnership Award (TRPA)
\$750K

IDA AND TRPA DEADLINES

June 2, 2022	October 6, 2022	December 2022	February 2023
Pre-Proposal Due	Full Applications Due	Peer Review	Programmatic Review



Clinical Trial Award (CTA)
\$1.5M

Cell Therapy Focus Option	\$2M
Qualified Collaboration Option	



Academy of Kidney Cancer Investigators - Early Career Scholar Award (AKCIECSA)
\$725K



Nurse Initiated Research Award (NIRA)
\$300K
Qualified Collaboration Option

CTA, AKCIECSA, AND NRA DEADLINES

September 29, 2022	October 20, 2022	December 2022	February 2023
Letter of Intent	Full Applications Due	Peer Review	Programmatic Review

CA, PCFA, IDA, TRPA, AKCIECSA, and CTA applications must address at least one of the FY22 KCRP Focus Areas; NRA applications are encouraged, but not required, to address at least one of the FY22 KCRP Focus Areas:

- Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors, and the prevention of kidney cancer.
- Identify and develop new strategies for screening, early-stage detection, and accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging.
- Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
- Develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
- Identify and implement strategies to improve the quality of life and survivorship for patients.
- Identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
- Support preparation and development of the next generation of kidney cancer researchers or cultivate collaborations in kidney cancer research or patient care in alignment with the KCRP Overarching Strategic Goals.